Regulatory Deficiency Letters Related to Outsourced Stability Testing
Pharmaceutical companies often rely on Contract Research Organizations (CROs) or third-party labs to conduct stability studies. However, this outsourcing model carries significant regulatory risk. Many regulatory deficiency letters from authorities like the USFDA or EMA cite critical issues with outsourced stability testing. This article explores the recurring failures, examples from real letters, and how to…
Read More “Regulatory Deficiency Letters Related to Outsourced Stability Testing” »